US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Innate Pharma

1.65

0.0000

Volume:- -

Turnover:- -

Market Cap:152.06M

PE:-2.61

High:1.65

Open:1.65

Low:1.65

Close:1.65

52wk High:2.25

52wk Low:1.37

Shares:92.16M

Float Shares:34.42M

Volume Ratio:0.03

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6319

EPS(LYR):-0.6319

ROE:-271.37%

ROA:-46.60%

PB:-3.27

PE(LYR):-2.61

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

Innate Pharma Price Target Maintained with a $9.00/Share by BTIG

Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate

Benzinga Earnings

Press Release: Innate Pharma Reports First Half 2026 Business Update and Financial Results

Innate Pharma, Sobi Partnership Becomes Effective

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/IPHYF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IPHYF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPHYF\",,,,,undefined,":{"symbol":"IPHYF","market":"US","secType":"STK","nameCN":"Innate Pharma","latestPrice":1.65,"timestamp":1789761600000,"preClose":1.65,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":34422236,"shares":92157798,"eps":-0.63191,"marketStatus":"Market Closed","change":0,"latestTime":"09-18 16:00:00 EDT Delay","open":1.65,"high":1.65,"low":1.65,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.63191,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1789977600000},"marketStatusCode":7,"adr":0,"adrRate":0,"listingDate":1533355200000,"exchange":"PINK LIMITED","adjPreClose":1.65,"volumeRatio":0.031055901585587003},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPHYF\",,,,,undefined,":{"symbol":"IPHYF","floatShares":34422236,"roa":"-46.60%","roe":"-271.37%","lyrEps":-0.63191,"volumeRatio":0.031055901585587003,"shares":92157798,"dividePrice":0,"high":1.65,"amplitude":0,"preClose":1.65,"low":1.65,"week52Low":1.3725,"pbRate":"-3.27","psRate":"13.50","week52High":2.25,"institutionHeld":0,"latestPrice":1.65,"eps":-0.63191,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.63191,"open":1.65,"prevYearClose":2.155,"prevWeekClose":1.65,"prevMonthClose":1.65,"prevQuarterClose":1.65,"fiveDayClose":1.65,"twentyDayClose":1.65,"sixtyDayClose":1.65},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPHYF\",params:#limit:5,,,undefined,":[{"date":"2024-05-14","symbol":"IPHYF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"Pre-MKt","dateTimestamp":1715659200000,"actualEps":null},{"market":"US","date":"2022-11-07","symbol":"IPHYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-MKt","type":"earning","dateTimestamp":1667797200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-09-15","symbol":"IPHYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1663214400000,"reportTimeType":"","actualEps":null},{"date":"2022-03-24","symbol":"IPHYF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1648108800000,"name":null,"time":"Pre-MKt","dateTimestamp":1648094400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPHYF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPHYF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3333,"buy":0.6667,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6667,"analysts":3,"updateTime":1761796800000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPHYF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2668996669","title":"Innate Pharma Price Target Maintained with a $9.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2668996669","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668996669?lang=en_us&edition=fundamental","pubTime":"2026-09-18 00:01","pubTimestamp":1789660860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IPHA/analyst-ratings","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPHYF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668956347","title":"Innate Pharma H1 EPS $(0.24) Misses $(0.16) Estimate, Sales $6.583M Miss $9.100M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2668956347","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668956347?lang=en_us&edition=fundamental","pubTime":"2026-09-17 13:12","pubTimestamp":1789621970,"startTime":"0","endTime":"0","summary":"Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.16) by 50 percent. This is a 14.29 percent increase over losses of $(0.28) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/09/61833106/innate-pharma-h1-eps-0-24-misses-0-16-estimate-sales-6-583m-miss-9-100m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPHYF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668955750","title":"Press Release: Innate Pharma Reports First Half 2026 Business Update and Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2668955750","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668955750?lang=en_us&edition=fundamental","pubTime":"2026-09-17 13:00","pubTimestamp":1789621200,"startTime":"0","endTime":"0","summary":"--  New strategic partnership with Sobi to advance lacutamab is effective,with a $75 million upfront payment; TELLOMAK-3 phase 3 initiated with FPI. --  EUR30 million equity financing completed to primarily support IPH4502. --  IPH4502 Phase 1 dose escalation and cohort enrichment enrollment. completed, with initial data to be presented at ENA 2026. --  PACIFIC-9 Phase 3 readout for monalizumab, led by AstraZeneca, expected. --  Anticipated cash horizon until the end of Q1 2028, taking into account. the initial payment of $75 million expected from the completion of the. transaction with Sobi and the proceeds from the EUR30 million capital. Access to live webcast: Click here to access the live webcast Participants may. also join via telephone using the registration link below: Click here to. register This information can also be found on the Investors section of the. Innate Pharma website, www.innate-pharma.com. A replay of the webcast will be. study in cutaneous T-cell lymphoma , a key","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPHYF","IPHA","BK4213","BK4139","CRT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2668935911","title":"Innate Pharma, Sobi Partnership Becomes Effective","url":"https://stock-news.laohu8.com/highlight/detail?id=2668935911","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2668935911?lang=en_us&edition=fundamental","pubTime":"2026-09-17 04:42","pubTimestamp":1789591337,"startTime":"0","endTime":"0","summary":"Innate Pharma SA  said Wednesday that its strategic partnership with Sobi to license lacutamab in T-cell lymphoma is now effective after applicable antitrust waiting periods expired and other closing conditions were completed.The closing triggers a $75 million upfront payment and starts the TELLOMAK-3 confirmatory Phase 3 study, with the first patient expected in Q1 2027, the company said.Innate will conduct the Phase 3 trial in cutaneous T-cell lymphoma, while Sobi will receive exclusive global commercialization rights upon potential accelerated approval, Innate said.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPHYF","IPHA","BK4139"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":9,"pageCount":1,"totalSize":36,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/IPHYF\",params:#limit:6,delay:false,,,undefined,":[]}}